NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN CHILDREN AND ADOLESCENTS
https://doi.org/10.17650/2073-8803-2017-12-3-51-57
Abstract
Fabry disease (Anderson–Fabry disease) is an X-linked recessive lysosomal storage disorder resulting from deficient activity of lysosomal hydrolase, alpha-galactosidase A, which leads to progressive accumulation of globotriaosylceramide (Gb3) in various cells (predominantly endothelial and vascular smooth muscle cells) with clinical manifestations affecting major organs including the central nervous system. Clinical onset of Fabry disease usually occurs in childhood, but many patients are diagnosed in adulthood. Early recognition of symptoms, enzyme activity levels, concentration of Gb3 in the blood, urine and skin bioptates, as well as genetic testing (GLA gene) enable establishment of early diagnosis and therapeutic intervention with enzyme replacement therapy. Early therapy may prevent complications of the disease.
About the Authors
A. S. Kotov
Moscow Regional Research and Clinical Institute named after M.F. Vladimirskiy
Russian Federation
61/2 Shchepkina St., Moscow 129110
Russian Federation
61/2 Shchepkina St., Moscow 129110
K. V. Firsov
Moscow Regional Research and Clinical Institute named after M.F. Vladimirskiy
Russian Federation
61/2 Shchepkina St., Moscow 129110
Russian Federation
61/2 Shchepkina St., Moscow 129110
References
1. Фирсов К.В., Котов А.С. Неврологические проявления при болезни Фабри. Журнал неврологии и психиатрии им. С.С. Корсакова 2016;116(9):98–105. [Firsov K.V., Kotov A.S. Neurological manifestations in the case of Fabry disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2004;104(6):54–8. (In Russ.)].
2. Allen L.E., Cosgrave E.M., Kersey J.P., Ramaswami U. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity. Br J Ophthalmol 2010;94(12):1602–5. DOI: 10.1136/bjo.2009.176651. PMID: 20576773.
3. Bersano A., Lanfranconi S., Valcarenghi C. et al. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand 2012;126(2):77–97. DOI: 10.1111/j.1600-0404.2012.01661.x. PMID: 22428782.
4. Biegstraaten M., Binder A., Maag R. et al. The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain 2011;15(8):822–9. DOI: 10.1016/j. ejpain.2011.01.014. PMID: 21334933.
5. Biegstraaten M., Linthorst G.E., van Schaik I.N., Hollak C.E. Fabry disease: a rare cause of neuropathic pain. Curr Pain Headache Rep 2013;17(10):365. DOI: 10.1007/s11916-013-0365-4. PMID: 23996721.
6. Bolsover F.E., Murphy E., Cipolotti L. et al. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis 2014;37(2):177–87. DOI: 10.1007/s10545-013-9643-x. PMID: 23949010.
7. Buda P., Wieteska-Klimczak A., Ksiazyk J., Smorczewska-Kiljan A. et al. Diagnostic problems in a 17-year-old patient with gastrointestinal manifestations of Fabry disease. Med Wieku Rozwoj 2011;15(1):69–72. PMID: 21786514.
8. Bugescu N., Alioto A., Segal S. et al. The neurocognitive impact of Fabry disease on pediatric patients. Am J Med Genet B Neuropsychiatr Genet 2015;168B(3):204–10. DOI: 10.1002/ajmg.b.32297. PMID: 25739920.
9. Bugescu N., Naylor P.E., Hudson K. et al. The psychosocial impact of Fabry disease on pediatric patients. J Pediatr Genet 2016;5(3): 141–9. DOI: 10.1055/s-0036-1584357. PMID: 27617155.
10. Burlina A.P., Sims K.B., Politei J.M. et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 2011; 11:61. DOI: 10.1186/1471-2377-11-61. PMID: 21619592.
11. Carubbi F., Bonilauri L. Fabry disease: raising awareness of the disease among physicians. Intern Emerg Med 2012;7 (suppl 3):S227–31. DOI: 10.1007/s11739-012-0821-x. PMID: 23073862.
12. Clavelou P., Besson G., Elziere C. et al. Neurological aspects of Fabry disease. Rev Neurol (Paris) 2006;162(5):569–80. PMID: 16710123.
13. Clavelou P., Besson G. Neurological aspects of Fabry disease. Presse Med 2007;36(spec No 1):1S65–8. PMID: 17546771.
14. Cybulla M., Kurschat C., West M. et al. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. J Nephrol 2013;26(4):645–51. DOI: 10.5301/ jn.5000214. PMID: 23023720.
15. Domínguez R.O., Michref A., Tanus E., Amartino H. Restless legs syndrome in Fabry disease: clinical feature associated to neuropathic pain is overlooked. Rev Neurol 2007;45(8):474–8. PMID: 17948213.
16. Dütsch M., Hilz M.J. Neurological complications in Fabry disease. Rev Med Interne 2010;31(suppl 2):S243–50. DOI: 10.1016/S0248-8663(10)70021-7. PMID: 21211673.
17. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson–Fabry disease. Cochrane Database Syst Rev 2016;7:CD006663. PMID: 23450571.
18. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson–Fabry disease. Cochrane Database Syst Rev 2013;2:CD006663. DOI: 10.1002/14651858.CD006663.
19. Ellaway C. Paediatric Fabry disease. Transl Pediatr 2016;5(1):37–42. DOI: 10.3978/j. issn.2224-4336.2015.12.02. PMID: 26835405.
20. Fancellu L., Borsini W., Romani I. et al. Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurol 2015;15:256. DOI: 10.1186/s12883-015-0513-z. PMID: 26652600.
21. Fellgiebel A., Albrecht J., Dellani P.R. et al. Quantification of brain tissue alterations in Fabry disea se using diffusion-tensor imaging. Acta Paediatr 2007;96(455): 33–6. PMID: 17391437.
22. Ferraz M.J., Kallemeijn W.W., Mirzaian M. et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct gly cosphingolipidoses. Biochim Biophys Acta 2014;1841(5): 811–25. DOI: 10.1016/j. bbalip.2013.11.004. PMID: 24239767.
23. Fuller M., Meikle P.J., Hopwood J.J. Epidemiology of lysosomal storage diseases: an overview. In: Fabry disease: perspec tives from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis, 2006. Pp. 9–20.
24. Germain D.P. Fabry disease. Orphanet J Rare Dis 2010;5:30. DOI: 10.1186/1750-1172-5-30. PMID: 21092187.
25. Ghali J., Murugasu A., Day T., Nicholls K. Carpal tunnel syndrome in Fabry disease. JIMD Rep 2012;2:17–23. DOI: 10.1007/8904_2011_37. PMID: 23430848.
26. Ghali J., Nicholls K., Denaro C. et al. Effect of reduced agalsidase beta dosage in Fabry patients: the Australian experience. JIMD Rep 2012;3:33–43. DOI: 10.1007/8904_2011_44.
27. Ginsberg L. Nervous system manifestations of Fabry disease: data from FOS – the Fa bry Outcome Survey. In: Fabry disease: perspectives from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. SunderPlassmann. Oxford: Oxford PharmaGenesis, 2006. Pp. 227–232.
28. Giuseppe P., Daniele R., Rita B.M. Cutaneous complicatio ns of Anderson–Fabry disease. Curr Pharm Des 2013;19(33):6031–6. PMID: 23448454.
29. Goker-Alpan O., Longo N., McDonald M. et al. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in chi ldren with Fabry disease who are naïve to enzyme replacement therapy. Drug Des Devel Ther 2016;10:1771–81. DOI: 10.2147/ DDDT.S102761. PMID: 27307708.
30. Hilz M.J., Brys M., Marthol H. et a l. Enzyme replacement therapy improves function of C-, Adelta-and Abeta-nerve fibers in Fabry neuropathy. Neurology 200413;62(7):1066–72. PMID: 15079003.
31. Hoffmann B., Mayatepek E. Fabry disease – a provocation for pediatrics. Klin Padiatr 2006;218(1):38 –40. PMID: 16432775.
32. Hoffmann B., Mayatepek E. Fabry disease – often seen, rarely diagnosed. Dtsch Arztebl Int 2009;106(26):440–7. DOI: 10.3238/arztebl.2009.0440. PMID: 19623315.
33. Hopki n R.J., Bissler J., Banikazemi M. et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2 008;64(5):550–5. DOI: 10.1203/PDR.0b013e318183f132. PMID: 18596579.
34. Hopkin R.J., Jefferies J.L., Laney D.A. et al. Th e management and treatment of children with Fabry disease: a United States-based perspective. Mol Genet Metab 2016;117(2):104–13. DOI: 10.1016/j.ymgme.2015.10.007. PMID: 26546059.
35. Hornbostel H., Sc riba K. Excision of skin in diagnosis of Fabry’s angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease. Klin Wochenschr 1953;31(3–4):68–9. PMID: 13062573.
36. Insert to use for Fabraz im № 003334/09, dated 30.04.2009.
37. Insert to use for Replagal № 00551/09, dated 29.01.2009.
38. Kalkum G., Pitz S., Karabul N. et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol 2016;16(1):202. PMID: 27852300.
39. Kampmann C., Wiethoff C.M., Whybra C. et al. Cardiac m anifestations of Anderson– Fabry disease in children and adolescents. Acta Paediatr 2008;97(4):463–9. DOI: 10.1111/j.1651-2227.2008.00700.x. PMID: 18363956.
40. Kampmann C., Perri n A., Beck M. Effectiveness of agals idase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis. 2015;10:125. DOI: 10.1186/s13023-015-0338-2.
41. Keilmann A., Hajioff D., Ramaswami U. et al. Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 2009;32(6): 739 –44. DOI: 10.1007/s10545-009-1290-x. PMID: 19876760.
42. Keilmann A., Hegemann S., Conti G., Hajioff D. Fabry disease and the ear. In: Fabry disease: perspectives from 5 years of FOS. Eds.: A. M ehta, M. Beck, G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis, 2006. Pp. 241–247.
43. Keilmann A. Inner ear function in children with Fabry disease. Acta Paediatr Suppl 2003;92(443):31–2; discussion 27. PMID: 14989463.
44. Kusano E., Saito O., Akimoto T., Asano Y. Fa bry disease: experience of screening dialysis patients for Fabry disease. Clin Exp Nephrol 2014;18(2):269–73. DOI: 10.1007/ s10157-013-0897-2. PMID: 24189976.
45. Laney D.A., Bennett R.L., Clarke V. et al. Fabry disease practice guidelines: reco mmendations of the National Society of Genetic Counselors. J Genet Couns 2013;22(5):555–64. DOI: 10.1007 / s10897-013-9613-3. PMID: 23860966.
46. Lidove O., Jaussaud R., Aractingi S. Dermatological and soft-tissue manifestations of Fabry disease: characteristic s and response to enzyme replacement therapy. In: Fabry disease: perspectives from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis; 200 6. Pp. 233–240.
47. Liguori R., Di Stasi V., Bugiardini E. et al. Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve 2010;41(3):409–12. DOI: 10.1002/ mus.21606. PMID: 20120004.
48. Low M., Nicholls K., Tubridy N. et al. Neu rology of Fabry disease. Intern Med J 2007;37(7):436–47. PMID: 17547722.
49. Luciano C.A., Russell J.W., Banerjee T.K. et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve 2002;26(5):622–9. PMID: 12402283.
50. MacDermot J., MacDermot K.D. Neuropathic pain in Anderson–Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001;429(1–3):121–5. PMID: 11698033.
51. Matern D., Gavrilov D., Oglesbee D. et al. Newborn screening for lysosomal storage disorders. Semin Perinatol 2015;39(3):206–16. DOI: 10.1053/j.semperi.2015.03.005. PMID: 25891428.
52. Mauhin W., Lidove O., Masat E. et al. Innate a nd adaptive immune response in Fabry disease. JIMD Rep 2015;22:1–10. DOI: 10.1007/8904_2014_371. PMID: 25690728.
53. Moller A.T ., Jensen T.S. Neurological manifestations in Fabry’s disease. Nat Clin Pract Neurol 2007;3(2):95–106. PMID: 17279083.
54. Motabar O., Sidransky E., Goldin E., Z heng W. Fabry disease – current treatment and new drug development. Curr Chem Genomics 201023;4:50–6. DOI: 10.2174/1875397301004010050. PMID: 21127742.
55. Müller M.J. Neuropsychiatric and psychosocial aspects of Fa bry disease. In: Fabry disease: perspectives from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. SunderPlassmann. Oxford: Oxford PharmaGenesis, 2006. Pp. 281–294.
56. Pintos Morell G. Fabry’s disease: diagnosis in the pediatric age grou p. An Esp Pediatr 2002;57(1):45–50. PMID: 12139892.
57. Pisani A., Visciano B., Roux G.D. et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature . Mol Genet Metab 2012;107(3):267–75. DOI: 10.1016/j.ymgme. 2012.08.003.
58. Politei J., Thurberg B.L., Wallace E. et al. Gastrointestinal involvement in Fabry disease. So important, yet often neglected. Clin Genet 2016;89(1):5–9. DOI: 10.1111/ cge.12673. PMID: 26333625.
59. Ramaswami U., Whybra C., P arini R. et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95(1):86–92. PMID: 16498740.
60. Riccio E., Capuano I., Visciano B. et al. Enzyme replaceme nt therapy in patients with Fabry disease: state of the art and review of the literature. G Ital Nefrol 2013;30(5):gin/30.5.5. PMID: 24402625.
61. Ries M., Ramaswami U., Parini R. et al. The early clinical phenotype o f Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003;162(11):767–72. PMID: 14505049.
62. Rombach S.M., Smid B.E., Linthorst G.E. et al. Natural course of Fabry disease and the effectiven ess of enzyme replacement therapy: a systematic review and metaanalysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 2014;37(3):341–52. DOI: 10.1007/ s10545-014-9677-8. PMID: 24492980.
63. Rozenfeld P. , Neumann P.M. Treatment of Fabry disease: current and emerging strategies. Curr Pharm Biotechnol 2011;12(6):916–22. DOI: 1389-2010/11 . PMID: 21235448.
64. Samuelsson K., Kostulas K., Vrethem M. et al. Idiopathic small fiber neuropathy: phenotype, etiologies, and the search for Fabry disease. J Clin Neurol 2014;10(2):108–18. DOI: 10.3988/ j cn.2014.10.2.108. PMID: 24829596.
65. Sawai S. Fabry disease: pathogenesis, clinical symptoms, and treatment with enzyme replacement therapy. Brain Nerve 2015;67(9):1099–108. DOI: 10.11477/ mf.1416200266. PMID: 26329150.
66. Schiffm ann R., Martin R.A., Reimschisel T. et al. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 2010;156(5):832–7. DOI: 10.1016/j.jpeds.2009.11.007. PMID: 20097359.
67. Schiffmann R., Moore D.F. Neurological manifestations of Fabry disease. In: Fabry disease: perspectiv es from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. SunderPlassmann. Oxford: Oxford PharmaGenesis; 2006. Pp. 215–225.
68. Schiffmann R., Pastores G.M., Lien Y.H. et al. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study. Orphanet J Rare Dis 2014;9:169. DO I: 10.1186/s13023-014-0169-6. PMID: 25425121.
69. Schiffmann R., Scott L.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 20 02;91(439):48–52. PMID: 12572843.
70. Sheth K.J., Bernhard G.C. The arthropathy of Fabry disease. Arthritis Rheum 1979;22(7):781–3. PMID: 110339.
71. Shribman S.E., Shah A. R., Werring D.J., Cockerell O.C. Fabry disease mimicking multiple sclerosis: lessons from 2 case reports. Mult Scler Relat Disord 2015;4(2):170–5. DOI: 10.1016/j. msard.2015.01.001. P MID: 25787193.
72. Sivley M.D. Fabry disease: a review of ophthalmic and systemic manifestations. Optom Vis Sci;90(2):e63–78. DOI: 10.1097/OPX.0b013e31827ec7eb. PMID : 23334311.
73. Sodi A., Ioannidis A., Pitz S. Ophthalmological manifestations of Fabry disease. In: Fabry disease: perspectives from 5 years of FOS. Eds.: A. Mehta, M. Beck, G. Sunder-Plassmann. Oxford: Oxford PharmaGenesis, 2006. Pp. 249–261.
74. Sweeley C.C., Klionsky B. Fabry’s disease: cla ssifications as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol Chem 1963;238:3148–50. PMID: 14081947.
75. Thomas A.S., Hughes D.A. Fabry disease. Pediatr Endocrinol Rev 2014;12(suppl 1):88–101. PMID: 25345090.
76. Thomas A.S., Mehta A.B. Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert Opin Med Diagn 2013;7(6):589–99. DOI: 10.1517/17530059.2013.846322. PMID: 24128193.
77. Tondel C., Bostad L., Hirth A., Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease an d minimal albuminuria. Am J Kidney Dis 2008;51(5):767–76. DOI: 10.1053/j.ajkd.2007.12.032. PMID: 18436087.
78. Tondel C., Bostad L., Larsen K.K. et al. Agalsidase benefits renal histology in young pa tients with Fabry disease. J Am Soc Nephrol 2013;24(1):137–48. DOI: 10.1681/ASN.2012030316. PMID: 23274955.
79. Tuttolomondo A., Pecoraro R., Simonetta I. et al. Anderson–Fabry disease: a multiorgan disease. Curr Pharm Des 2013;19(33):5974–96. PMID: 23448451.
80. Üçeyler N., He L., Schönfeld D. et al. Small fibers in Fabry disease: baseline and followup data under enzyme replacement the rapy. J Peripher Nerv Syst 2011;16(4):304–14. DOI: 10.1111/j.1529-8027.2011.00365.x. PMID: 22176145.
81. Van der Tol L., Svarstad E., Ortiz A. et al. Chronic kidney disease and an uncertain di agnosis of Fabry disease: approach to a correct diagnosis. Mol Genet Metab 2015;114(2):242–7. DOI: 10.1016/j.ymgme.2014.08.007. PMID: 25187469.
82. Waldek S., Feriozzi S. Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy? BMC Nephrol 2014;15:72. DOI: 10.1186/1471-2369-15-72. P MID: 24886109.
83. Weidemann F., Sanchez-Niño M.D., Politei J. et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 2013;8:116. DOI: 10.1186/1750-1172-8-116. PMID: 23915644.
84. Wraith J.E., Tylki-Szymanska A., Guffon N. et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008;152(4):563–70. DOI: 10.1016/j.jpeds.2007.09.007. PMID: 18346516.
Review
For citations:
Kotov A.S., Firsov K.V. NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN CHILDREN AND ADOLESCENTS. Russian Journal of Child Neurology. 2017;12(3):51-57. (In Russ.) https://doi.org/10.17650/2073-8803-2017-12-3-51-57
Views:
991
Email this article 